Horizon won an appeals court ruling that upheld one of its patents for the arthritis drug Pennsaid 2% but lost one of its patents on the urea treatment Ravicti.
- In the first of two rulings issued Oct. 10, the U.S. Court of Appeals for the Federal Circuit rejected arguments by
Teva ’s Actavis unit that Horizon patent 9,066,913 didn’t cover a new idea - Teva had conceded infringement of the patent, which expires in 2027, leaving only the issue of validity at
trial - Ruling means Teva can’t sell its generic version of the drug until 2027
- Horizon sought to revive other ...